Abu Dhabi's Full Exit Leaves Evotec Investors to Weigh Two Unrelated Signals
Published on 10/22/2026 at 19:10 | Editorial boerse-global.de
Abu Dhabi's government has disclosed that its indirect stake in Evotec, held through Mubadala Investment Company, has fallen from 5.62% to 0.00%. The threshold notification names 9 October as the date the holding crossed the reporting line. The filing addresses ownership structure only and offers no rationale for the move, so it cannot be read as a verdict on the business itself.
That distinction matters because Evotec's operating news has been moving in the opposite direction. Preliminary nine-month figures published roughly a week ago came in ahead of market expectations, a beat that Reuters linked to the share price strength at the time. The voting-rights disclosure, by contrast, says nothing about the quality of those numbers.
A beat that stops short of a profit
For the first nine months of 2026, Evotec reported group revenue of around EUR 465.0 million and an adjusted group EBITDA of approximately EUR ?42.8 million. The positive surprise therefore did not mark a return to positive adjusted operating earnings.
Should investors sell immediately? Or is it worth buying Evotec?
Evotec attributed the gap against consensus largely to the timing of analyst estimates — a caveat that belongs alongside the headline beat. The company did not pair the stronger figures with a raised full-year outlook. Instead, it confirmed group revenue of around EUR 570 million to EUR 610 million for the year, and an adjusted group EBITDA of roughly EUR ?70 million to EUR ?105 million.
Berenberg's Christian Ehmann captured the tension in a note dated 16 October. He called the preliminary results surprisingly strong, yet kept a hold rating and a EUR 3.60 price target. Praise for the figures and restraint on the investment case, it seems, are not mutually exclusive. Ehmann pointed to tailwinds from drug discovery and preclinical development — the most operationally interesting part of his assessment, since it shifts attention from the size of the beat to where an improvement could actually originate. Even so, a tailwind is not a proven, durable earnings trend.
What the November update must show
Evotec is scheduled to publish its quarterly statement for the third quarter and the first nine months of 2026 on 5 November. That release is the next announced checkpoint for testing the preliminary figures.
Investors are thus left holding two separate signals. A previously larger shareholder has reported its stake falling to zero. At the same time, the operating picture beat expectations without any accompanying upgrade to guidance. The test on 5 November is not simply whether Evotec clears the bar again; the more telling question is whether the company can draw a convincing line between the operational tailwinds it describes and an actual improvement in earnings. Until then, the difference between beating expectations and genuinely improving the outlook remains the crux of the story.
Ad
Evotec Stock: New Analysis - 22 October
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
